Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06557265 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
A Phase 1 study of Lupus Nephritis and Primary Membranous Nephropathy, sponsored by Nkarta.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 16
- Study locations
NCT06557265 is a Phase 1 study of Lupus Nephritis and Primary Membranous Nephropathy that is actively recruiting participants, run by Nkarta. The registered enrollment target is 96 participants, below the 307-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (69% lower). The trial reports 16 study locations across 10 states.
The verdict
NCT06557265, a Phase 1 study of Lupus Nephritis and Primary Membranous Nephropathy, is actively recruiting participants, sponsored by Nkarta.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is an open-label, multi-center, non-randomized, Phase 1/2 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with active lupus nephritis (LN) or primary membranous nephropathy (pMN).
Conditions Studied
Interventions
- DRUG NKX019
- DRUG Fludarabine, Cyclophosphamide
Study Locations (16)
Florida
- Nkarta Investigational Site - Gainesville
- Nkarta Investigational Site - Miami
- Nkarta Investigational Site - Plantation
- Nkarta Investigational Site - Tampa
New York
- Nkarta Investigational Site - New York
- Nkarta Investigational Site - Stony Brook
- Nkarta Investigational Site - Syracuse
Texas
- Nkarta Investigational Site - Dallas
- Nkarta Investigational Site - Houston
Arkansas
- Nkarta Investigational Site - Little Rock
Georgia
- Nkarta Investigational Site - Atlanta
Illinois
- Nkarta Investigational Site - Chicago
Louisiana
- Nkarta Investigational Site - New Orleans
Massachusetts
- Nkarta Investigational Site - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2024-06-13 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06557265
The ClinicalTrials.gov registry entry for NCT06557265 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 307-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (69% lower). The listed sponsor is Nkarta, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 2 interventions - of which NKX019 is the first listed.
NCT06557265 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Florida, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT06557265 about?
NCT06557265 is a clinical study titled "A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)". This is an open-label, multi-center, non-randomized, Phase 1/2 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with active lupus nephritis (LN) or primary membranous nephropathy (pMN).
What is the current status of trial NCT06557265?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2024-06-13. Estimated completion is 2027-04.
What conditions does trial NCT06557265 study?
This clinical trial studies the following conditions: Lupus Nephritis, Primary Membranous Nephropathy.
What interventions are being tested in trial NCT06557265?
The interventions under investigation include: NKX019 (DRUG), Fludarabine, Cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT06557265?
This trial is sponsored by Nkarta, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06557265 being conducted?
This trial has 16 study locations across Arkansas, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
ACTIVE NOT RECRUITING · Phase 1
-
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 1
-
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.